Precision BioSciences Q4 Revenue Soars Past Estimates by Over 3x
summarizeSummary
Precision BioSciences reported strong fourth-quarter results, with revenue of $34.204 million significantly exceeding the IBES estimate of $9.07 million. The company also posted a net income of $20.133 million and income from operations of $12.508 million. This substantial revenue beat, more than tripling analyst expectations, is a highly positive development for the company and is likely to be a significant catalyst for the stock. This news provides fresh financial performance data, following yesterday's patent allowance announcement. Traders will be closely watching for further details on the drivers of this revenue growth and any updated guidance.
At the time of this announcement, DTIL was trading at $5.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $121.8M. The 52-week trading range was $3.53 to $8.82. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.